Clinical manifestations and treatment of retinoblastoma in Korea

British Journal of Ophthalmology

Volumn 92, Issue 9, 2008, Pages 1180-1184

  Chung, S E ^a   Sa, H S ^a   Koo, H H ^a   Yoo, K H ^a   Sung, K W ^a   Ham, D I ^a  

^a Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; VINCRISTINE;

ARTICLE; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CHILD; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; INFANT; INTERNATIONAL CLASSIFICATION OF DISEASES; KOREA; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; PROGNOSIS; RETINOBLASTOMA; RETROSPECTIVE STUDY; SYMPTOMATOLOGY; TREATMENT DURATION; TREATMENT OUTCOME; URINARY DYSFUNCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; ETOPOSIDE; EYE; EYE ENUCLEATION; FEMALE; HUMANS; INFANT; KOREA; MALE; NEOPLASM RECURRENCE, LOCAL; RETINAL NEOPLASMS; RETINOBLASTOMA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 51149089148     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.2008.140046     Document Type: Article

References (30)

1. Mahoney MC, Burnett WS. Majerovics A, et al. The epidemiology of ophthalmic malignancies in New York State. Ophthalmology 1990;97:1143-7.
2. Balmer A, Zografos L, Munier F. Diagnosis and current management of retinoblastoma. Oncogene 2006;25:5341-9.
3. Gallie BL, Budning A, DeBoer G, et al. Chemoreduction with focal therapy can cure intraocular retinoblastoma without radiotherapy. Arch Ophthalmol 1996;114:1321-8.
4. Kingston JE, Hungerford JL, Madreperla SA, et al. Results of combined chemoreduction and radiotherapy for advanced intraocular retinoblastoma. Arch Ophthalmol 1996;114:1339-43.
5. Murphree AL, Villablanca JG. Deegan WF III, et al. Chemoreduction plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1348-56.
6. Shields CL, De Potter P, Himelstein BP, et al. Chemoreduction in the initial management of intraocular retinoblastoma. Arch Ophthalmol 1996;114:1330-8.
7. Greenwald MJ, Strauss LC. Treatment of intraocular retinoblastoma with carboplatin and etoposide chemoreduction. Ophthalmology 1996;103:1989-97.
8. Chan HS, DeBoer G, Thiessen JJ, et al. Combining cyclosporin with chemoreduction controls intraocular retinoblastoma without requiring radiation. Clin Cancer Res 1996;2:1499-508.
9. Shields CL, Shields JA, Needle M, et al. Combined chemoreduction and adjuvant treatment for intraocular retinoblastoma. Ophthalmology 1997;104:2101-11.
10. Gunduz K, Shields CL, Shields JA, et al. The outcome of chemoreduction treatment in patients with Reese-Ellsworth group V retinoblastoma. Arch Ophthalmol 1998;116:1613-17.
11. Levy C, Doz F, Quintana E, et al. Role of chemoreduction alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results. Br J Ophthalmol 1998;82:1154-8.
12. Friedman DL, Himelstein B, Shields CL, et al. Chemoreduction and local ophthalmic therapy for intraocular retinoblastoma. J Clin Oncol 2000;18:12-17
13. Beck MN, Balmer A, Dossing C, et al. First-line chemoreduction with local treatment can prevent external-beam irradiation and enucleation in low-stage intraocular retinoblastoma. J Clin Oncol 2000;18:2881-7.
14. Wilson MW, Rodriguez-Galindo C, Haik BG, et al. Multiagent chemoreduction as neoadjuvant treatment for multifocal intraocular retinoblastoma. Ophthalmology 2001;108:2106-14.
15. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction plus focal therapy for retinoblastoma: factors predictive of need for treatment with external beam radiotherapy or enucleation. Am J Ophthalmol 2002;133:657-64.
16. Shields CL, Honavar SG, Shields JA, et al. Factors predictive of recurrence of retinal tumors, vitreous seeds, and subretinal seeds following chemoreduction for retinoblastoma. Arch Ophthalmol 2002;120:460-4.
17. Shields CL, Honavar SG, Meadows AT, et al. Chemoreduction for unilateral retinoblastoma. Arch Ophthalmol 2002;120:1653-8.
18. Brichard B, De Bruycker JJ, De Potter P, et al. Combined chemoreduction and local treatment in the management of intraocular retinoblastoma. Med Pediatr Oncol 2002;38:411 15.
19. Gombos DS, Kelly A, Coen PG, et al. Retinoblastoma treated with primary chemoreduction alone; the significance of tumour size, location, and age. Br J Ophthalmol 2002;86:80-3.
20. Rodriguez-Galindo C, Wilson MW, Haik BG, et al. Treatment of Intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003;21:2019-25.
21. Shields CL, Shields JA. Recent developments in the management of retinoblastoma. J Pediatr Ophthalmol Strabismus 1999;36:8-18.
22. Epstein J, Shields CL, Shields JA. Trends in the management of retinoblastoma: evaluation of 1,196 consecutive eyes during 1974-2001. J Pediatr Ophthalmol Strabismus 2003;40:196-203.
23. Ozkan A, Pazarli H, Celkan T, et al. Retinoblastoma in Turkey: survival and clinical characteristics 1981-2004. Pediatr Int 2006;48:369-73.
24. Song JS, Lee JK, Lee TW. Treatment and prognosis of retinoblastoma; clinicopathologic analysis of 101 cases. J Korean Ophthalmol Soc 1998; 39:2393-405.
25. Shields CL, Meadows AT, Leahcv AM, et al. Continuing challenges in the management of retinoblastoma with chemoreduction. Retina 2004;24:849-62.
26. Reese AB, Ellsworth RM. The evaluation and current concept of retinoblastoma therapy. Trans Am Acad Ophthalmol Otolaryngol 1963;67:164-72.
27. Shields CL, Mashayekhi A, Demirci H, et al. Practical approach to management of retinoblastoma. Arch Ophthalmol 2004;122:729-35.
28. Shields CL, Mashayekhi A, Au AK, et al. The international classification of retinoblastoma predicts chemoreduction success. Ophthalmology 2006; 113:2276-80.
29. Su WW, Kao AY. Retinoblastoma in Taiwan: the effect of a government-sponsored national health Insurance program on the treatment and survival of patients with retinoblastoma. J Pediatr Ophthalmol Strabismus 2006;43:358-62.
30. Shields CL, Meadows AT, Shields JA, et al. Chemoreduction for retinoblastoma may prevent intracranial neuroblastic malignancy (trilateral retinoblastoma). Arch Ophthalmol 2001;119:1269-72.